Compare ARDX & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDX | CET |
|---|---|---|
| Founded | 2007 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | CET |
|---|---|---|
| Price | $7.32 | $52.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $12.95 | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 49.4K |
| Earning Date | 02-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.40 |
| Revenue | ★ $398,234,000.00 | $27,062,484.00 |
| Revenue This Year | $22.44 | N/A |
| Revenue Next Year | $34.00 | N/A |
| P/E Ratio | ★ N/A | $6.99 |
| Revenue Growth | ★ 58.12 | 15.78 |
| 52 Week Low | $3.21 | $40.24 |
| 52 Week High | $8.40 | $52.95 |
| Indicator | ARDX | CET |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 50.14 |
| Support Level | $6.92 | $51.35 |
| Resistance Level | $8.02 | $52.71 |
| Average True Range (ATR) | 0.41 | 0.73 |
| MACD | -0.13 | -0.08 |
| Stochastic Oscillator | 17.31 | 37.57 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.